Modified immune cell platform

By improving the expression or activity of L-type Cav channels and activate the Hh signaling pathway, the problem of insufficient effectiveness in existing immune cell therapy is solved, and the cytotoxicity and killing ability of immune cells is significantly enhanced. It is suitable for a variety of cancers and proliferation Treatment of sexual diseases.

CN119013039APending Publication Date: 2024-11-22CANCER RESEARCH TECHNOLOGY LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202380031448.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-28
Filing Date
2023-03-28
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing immune cell therapy still has the problem of insufficient effectiveness in the treatment of cancer and other proliferative diseases, especially in the lack of effective methods in improving cytotoxicity and enhancing immune cell killing capacity.

Method used

By increasing the expression or activity of L-type Cav channels, for example by overexpressing Cav1.4, Cav1.3, Cav1.2 or Cav1.1 channels, and introducing functionally acquired mutations such as I745T mutation in CACNA1F, or by activating Hh GLI1 expression in the signaling pathway enhances the cytotoxicity of immune cells.

Benefits of technology

It significantly enhances the cytotoxicity of immune cells, improves the killing ability of tumor cells and virus-infected cells, enhances the therapeutic efficacy of immune cells, and is suitable for the treatment of a variety of cancer and proliferative diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119013039A_ABST
    Figure CN119013039A_ABST
Patent Text Reader

Abstract

The present invention provides engineered immune cells, wherein the engineered immune cells comprise a functionally acquired mutation in the Cav channel and / or an overexpression L-type voltage gated calcium (Cav) channel. Related engineered immune cells for use in medicine are also provided. Also provided are L-type Cav channel agonists for use in methods of stimulating cell killing activity of immune cells in a subject suffering from a proliferative disorder. Pharmaceutical compositions and methods are also provided.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to products and methods for regulating (including enhancing) immune cell cytotoxicity. In particular, enhancement of L-type Cav channel expression or activity for medical use is disclosed. The present invention provides modified immune cells, agents and methods for modifying immune cells, and medical uses thereof. Background Art

[0002] Cytotoxic T lymphocytes (CTLs) play a key role in the immune response against cancer and intracellular pathogens. CTLs recognize tumors and infected cells through their T cell receptor (TCR) complexes, and this recognition induces a cascade of intracellular signaling pathways. One such pathway is the Hedgehog (Hh) signaling pathway. Induction of Hh leads to enhanced expression of the Hh transcription factor Gli1 (de la Roche, 2013). Therefore, GLI1 expression is a faithful reporter of Hh signaling. The inventors have previously shown that Gli1 induction is Ca 2+ dependent (Hanna, 2021), and is CD8 + They also showed that this non-canonical Hh signaling pathway activates Ca2+ through L-type voltage-gated Ca2+. 2+ Channels work.

[0003] There are four members of the L-type voltage-gated calcium channel family. They are Cav1.1, Cav1.2, Cav1.3 and Cav1.4. All four members are expressed in mouse T cells (Badou, 2013), while only Cav1.4 and Cav1.3 are expressed in human CD8+ T cells, and the expression level is lower (Hanna, 2021).

[0004] Cytotoxic lymphocytes including CD8 + T cells, CD4 + T cells and natural killer (NK) cells, both of which act on tumors and virus-infected cells by recognizing different targets. + T cells recognize major histocompatibility complex class I (MHCI) antigens, while CD4 + T cells recognize MHC class II antigens. In contrast, NK cells recognize and kill MHC-negative cells.

[0005] Immune cell therapy is the most advanced of the cell therapy categories, with clear evidence of clinical benefit in cancer and infectious diseases. Immune cell types that can be used as therapeutic agents include αβT cells, NK cells, γδ(gd)T cells, NK T (NKT) cells, and immune effectors derived from induced pluripotent stem cells (iPSC). Immune cell therapy has a wide range of applicability and includes the treatment of cancer, infection, allogeneic transplantation, and autoimmunity.

[0006] T cell therapy has become the most advanced treatment within this therapeutic category. To treat cancer, T cell immunotherapy can be developed in different ways: unmodified tumor infiltrating lymphocytes (TIL), T cells expressing modified T cell receptors (TCR), and chimeric antigen receptor (CAR) T cells.

[0007] NK cells are also being investigated for use in cancer therapy. The main advantage of NK cells is that they have cytotoxic capacity but do not mediate severe graft versus host disease (GVHD) when administered to patients as an allogeneic transplant, potentially enabling the development of “off-the-shelf” products.

[0008] There are currently 4 adoptive cell therapies approved by the FDA for the treatment of lymphoma, leukemia, and myeloma subtypes. Despite these advances, there remains a need for methods and agents for improving the effectiveness of cell therapies (eg, for treating disorders such as cancer).

[0009] The present invention has been designed based on the above considerations. Summary of the invention

[0010] The present inventors attempt to provide such a platform, which enhances immune cell cytotoxicity by increasing the expression or activity of L-type Cav channels, which can be used in adoptive cell therapy.

[0011] Thus, in a first aspect, the present invention provides an engineered immune cell that overexpresses an L-type voltage-gated calcium (Cav) channel and / or comprises a gain-of-function (GOF) mutation in an L-type Cav channel.

[0012] In some embodiments, the engineered immune cells overexpress Cav1.4 compared to wild-type immune cells of the same type. In other embodiments, the engineered immune cells overexpress Cav1.3 compared to wild-type immune cells of the same type. In other embodiments, the engineered immune cells overexpress Cav1.2 compared to wild-type immune cells of the same type. In other embodiments, the engineered immune cells overexpress Cav1.1 compared to wild-type immune cells of the same type.

[0013] In some embodiments, the engineered immune cells comprise a mutation in a gene encoding an L-type Cav channel. In some embodiments, the engineered immune cells comprise a gain-of-function mutation in CACNA1F (a gene encoding Cav1.4). In some embodiments, the CACNA1F mutation comprises I745T (using EU numbering) (Hemara-Wahanui, 2005). This mutation is listed in SEQ ID NO:5. This mutation is also referred to in the literature as I756T (Williams, 2020). Pore-forming Ca 2+ The protein structure of the channel α1 subunit is highly conserved, and therefore one could predict that the same I745T GOF mutation in CACNA1F would result in gain-of-function in other L-type Cav channels, as this region is highly conserved.

[0014] Other gain-of-function mutations encompassed by the present invention are listed in Table 1 below.

[0015] Table 1: Overview of gain-of-function (GOF) mutations in L-type Cav channels (Cav1.4, Cav1.3, and Cav1.2) (Striessnig, 2021)

[0016] mutation aisle Notes G369D Cav1.4 The patient mutation is also present in Cav1.2 and Cav1.3 F753C Cav1.4 The patient mutation is also present in Cav1.3 I745T(I756T) Cav1.4 The patient mutation is also present in Cav1.3 G403D Cav1.3 The patient mutation is also present in Cav1.3 and Cav1.2 G407R Cav1.3 Less severe phenotype, patient mutation also present in Cav1.2 V401L Cav1.3 - A749T Cav1.3 - A749G Cav1.3 Less severe phenotype I750M Cav1.3 The patient mutation is also present in Cav1.4 G402R / S Cav1.2 The patient mutation is also present in Cav1.3 and Cav1.4 E407A Cav1.2 - I1186T Cav1.2 -

[0017] Since L-type Cav channels in T cells may not be voltage-gated (Kotturi, 2005), preferred mutations are not in the voltage sensor region of L-type Cav channels. Preferred mutations are located within the activation gate (i.e., the cytoplasmic region of the S6 helix), within the S5-S6 linker (Striessnig, 2021); or within the S5-S6 pore. 2+ Channel-converting GOF mutations are not preferred because Ca 2+ Transport is essential for the induction of Gli1 (Hanna, 2021).

[0018] In other aspects, the invention provides engineered immune cells comprising a mutation in a gene encoding a component of the Hh signaling pathway that results in increased GLI1 expression and / or activity, which can be measured by a Gli1 reporter assay. For example, the mutation can be in the PTCH1 gene, which encodes protein patched homolog 1 (PTCH1). PTCH1 enhances canonical Hh signaling.

[0019] In a related aspect, the invention provides an engineered immune cell for use in medicine (e.g., for treating a proliferative disorder in a mammal), comprising a mutation in a gene encoding a component of the Hh signaling pathway that results in increased expression and / or activity of GLI1. In some embodiments, the mutation may be in the PTCH1 gene, which encodes protein patch homolog 1 (PTCH1) (e.g., PTCH1 mutations have been found to be present in subjects with Gorlin syndrome, or mutations have been artificially introduced into PTCH1 to silence, downregulate, or otherwise reduce the ability of PTCH1 to act as a negative regulator of GLI1.

[0020] In some embodiments, the engineered immune cell is selected from T cells (including gamma delta (γδ) T cells), chimeric antigen receptor (CAR)-T cells, NK cells, and CAR-NK cells. The inventors unexpectedly found that calcium-dependent Gli1 signaling is conserved between T cells and NK cells. In some embodiments, the engineered immune cell is a T cell. In some embodiments, the T cell is a CD8 + In some embodiments, the T cells are CD4 + In some embodiments, the T cells are cytotoxic CD4 + T cells. In some embodiments, the T cells are γδ T cells.

[0021] In a second aspect, the present invention provides a modified immune cell for use in medicine, wherein the modified immune cell overexpresses an L-type Cav channel and / or comprises a gain-of-function mutation in an L-type Cav channel. In some embodiments, the modified immune cell is used in a method for treating a chronic infection in a subject. For example, the modified immune cell can be used to treat a method for treating SARS-CoV-II, HIV, hepatitis C, hepatitis B, human cytomegalovirus (CMV), or an opportunistic fungal infection (e.g., aspergillosis). In some embodiments, the modified immune cell is used in a method for treating an autoimmune disease in a subject. For example, engineered immune cells can be used to treat rheumatoid arthritis (RA), type 1 diabetes, psoriasis, psoriatic arthritis, multiple sclerosis (MS), systemic lupus erythematosus (SLE), lupus nephritis, inflammatory bowel disease (IBD), autoimmune Addison's disease (AAD), Grave's disease, Sjögren's syndrome ( syndrome, Hashimoto's thyroiditis, myasthenia gravis, or autoimmune vasculitis.

[0022] In a third aspect, the present invention provides a modified immune cell for a method of treating cancer in a subject, wherein the modified immune cell overexpresses an L-type Cav channel and / or comprises a gain-of-function mutation in an L-type Cav channel. Specific target cancers of interest include those with high infiltration of cytotoxic lymphocytes. This includes melanoma, lung cancer, colorectal cancer, and breast cancer. Other target cancers are those that are sensitive to CAR T and NK cell therapy. These cancers include blood cancers, such as lymphomas, leukemias (such as ALL and CLL), and multiple myeloma; and solid tumors targeted by CAR, including lung cancer, liver cancer, gastric cancer (including those EGFR) / CNS, pediatric gliomas (HER2) / ovarian cancer, cervical cancer, pancreatic cancer, lung cancer (mesothelin), colon cancer, pancreatic cancer, prostate cancer, gastric cancer, liver cancer (EpCAM), etc.

[0023] In some embodiments, the engineered immune cell overexpresses Cav1.4 compared to a wild-type immune cell of the same type.

[0024] In some embodiments, the engineered immune cell comprises a gain-of-function mutation in CACNA1F. In some embodiments, the CACNA1F mutation comprises I745T.

[0025] In some embodiments, the engineered immune cells are selected from the group consisting of: T cells (including gamma delta (γδ) T cells), CAR-T cells, NK cells, and CAR-NK cells.

[0026] In some embodiments, the method for treating cancer in an object is an in vivo method. As described herein, such a method may include, for example, adoptive transfer of T cells. In these embodiments, the method may include removing immune cells from the object and subsequent operations. The operation may include genetic modification to introduce functional gain mutations in the L-type Cav channel, or overexpressing the L-type Cav channel. In some embodiments, the method may include the step of administering manipulated immune cells to the object. The object may be the same object or a different object as the object from which the immune cells were taken out, i.e., the method may be allogeneic or autologous. In some embodiments, the method for stimulating T cell killing activity is an ex vivo method, i.e., the method includes the step of operating immune cells in vitro in the object. In such a method, it is expected that the immune cells can be administered back to the object after the ex vivo operation.

[0027] In a fourth aspect, the present invention provides an L-type Cav channel agonist for a method of stimulating the cell killing activity of immune cells in a subject suffering from a proliferative disease. In some embodiments, the method of stimulating cell killing activity is an in vivo method. The immune cell may be a T cell (including a gamma delta (γδ) T cell), a CAR-T cell, a NK cell or a CAR-NK cell. As described herein, such a method may include, for example, the adoptive transfer of T cells. In these embodiments, the method may include removing immune cells from the subject and subsequent manipulation. The manipulation may include treatment with an L-type Cav channel agonist. In some embodiments, the method may include the step of administering manipulated immune cells to the subject. The subject may be the same subject or a different subject as the subject from which the immune cells were removed, i.e., the method may be allogeneic or autologous. In some embodiments, the method of stimulating T cell killing activity is an ex vivo method, i.e., the method includes the step of manipulating immune cells in vitro of the subject. In such a method, it is expected that the immune cells can be administered back to the subject after the ex vivo manipulation. In some embodiments, the L-type Cav channel agonist used according to this aspect of the invention exhibits Gli1 enhancing activity in immune cells, as determined by a Gli1 reporter assay. For example, a GHl reporter assay as defined herein.

[0028] In a fifth aspect, the present invention provides a pharmaceutical composition comprising immune cells treated with L-type Cav channel agonists or immune cells mixed with L-type Cav channel agonists. The immune cells may be T cells (including gamma delta (γδ) T cells), CAR-T cells, NK cells or CAR-NK cells. In some embodiments, the composition is used to stimulate a method for cell killing activity against a target cell population (e.g., a diseased cell population, such as a cancer cell population). The composition can be used in vivo, in vitro or in vitro methods.

[0029] In a sixth aspect, the present invention provides an in vitro method for improving the cell killing activity of immune cells, comprising contacting an L-type Cav channel agonist with an immune cell, wherein the Cav channel agonist is capable of stimulating L-type Cav channel activity in a Gli1 reporter assay. In some embodiments, the L-type Cav channel agonist is incubated with the immune cell for a period of time sufficient to cause cell killing activity and / or cell killing potential to increase. For example, incubation can be 10, 20, 30 minutes, or 1, 2, 5, 12, 24, 48 hours or longer.

[0030] In some embodiments, according to any aspect of the present invention, the L-type Cav channel agonist is a compound as disclosed in EP0230110 A1 and EP 0300688 A1, the contents of which are incorporated herein by reference. For example, the L-type Cav channel agonist can be a compound defined by the formula in claim 1 of EP 0230110 A1. For example, the L-type Cav channel agonist can be a compound defined by the formula in claim 1 of EP 0300688A1. In some embodiments, the L-type Cav channel agonist is selected from FPL64176 and Bay K8644.

[0031] In a seventh aspect, the present invention provides an in vitro method for engineering immune cells to enhance cell killing activity, comprising genetically engineering immune cells to enhance expression of L-type Cav channel activity or stimulate L-type Cav channel activity in a Gli1 reporter assay.

[0032] In some embodiments, the modification comprises overexpressing Cav1.4. In some embodiments, the method of overexpression comprises using a vector to stably express Cav1.4. In some embodiments, the vector is a lentiviral vector, a retroviral vector, or a transposon-based vector.

[0033] In some embodiments, the modification comprises mutating Cav1.4 to introduce a gain-of-function mutation. In some embodiments, the Cav1.4 mutation comprises I745T.

[0034] In other embodiments, the modification comprises nuclease-based editing. In some embodiments, the modification comprises CRISPR-based editing. In some embodiments, the modification comprises lead editing (Anzalone, 2019).

[0035] In some embodiments, the immune cell is selected from T cells (including gamma delta (γδ) T cells), CAR-T cells, NK cells, and CAR-NK cells.

[0036] In other related aspects, the present invention provides a method for treating a proliferative disease in a mammalian subject, comprising administering to a subject in need thereof a therapeutically effective amount of engineered immune cells, wherein the immune cells overexpress an L-type Cav channel and / or comprise a gain-of-function mutation in an L-type Cav channel.

[0037] In some embodiments, the immune cell is selected from T cells (including gamma delta (γδ) T cells), CAR-T cells, NK cells, and CAR-NK cells.

[0038] In other related aspects, the invention provides methods of treating a proliferative disease in a mammalian subject comprising administering to a subject in need thereof a therapeutically effective amount of an L-type Cav channel agonist.

[0039] In another aspect, the present invention provides a method for treating a proliferative disease in a mammalian subject, comprising administering to a subject in need thereof a therapeutically effective amount of an immune cell treated with an L-type Cav channel agonist. In some embodiments, the immune cell is derived from a subject in need thereof, i.e., it is an autologous method of treatment. In some embodiments, the immune cell is not derived from a subject in need thereof, i.e., it is an allogeneic method of treatment. In a preferred embodiment, the immune cell is a NK cell.

[0040] In some embodiments, the L-type Cav channel agonist is selected from FPL 64176 and Bay K8644.

[0041]

[0042]

[0043] In other aspects, the present invention provides a method for determining the cytotoxic fitness of immune cells from a mammalian subject, comprising measuring the level of GLI1 expression in immune cells from a mammalian subject. The method can be performed in vitro or in vivo. In particular, GLI1 expression can be measured using a Gli1 reporter assay as defined herein. Cytotoxic fitness refers to the cytotoxicity level of an immune cell. In this way, GLI1 expression is provided as a biomarker of the cytotoxic capacity of the immune system or immune cells of a subject.

[0044] In some embodiments, the immune cell is a modified immune cell. In some embodiments, the method includes administering a test agent to the immune cell. In some embodiments, the test agent is an L-type Cav channel agonist. In some embodiments, the modified immune cell is a CAR T cell, a CARNK cell, a T cell (including a gamma delta (γδ) T cell) or a NK cell. Therefore, the present invention provides GLI1 as a biomarker to determine the cytotoxic effectiveness of cells used for adoptive cell therapy.

[0045] In another aspect, the present invention provides a modified immune cell for treating a proliferative disease in a subject, wherein the modified immune cell comprises a loss-of-function mutation in PTCH1 and / or wherein PTCH1 has been silenced or downregulated and / or wherein the PTCH1 gene product has been antagonized. In some embodiments, the loss-of-function mutation in PTCH1 is a mutation found to be present in a human patient with Gorlin syndrome. In some embodiments, the modified immune cell used is selected from T cells (including gamma delta (γδ) T cells), CAR-T cells, NK cells and CAR-NK cells. In some embodiments, the proliferative disease comprises cancer, optionally wherein the cancer is selected from: melanoma, lung cancer, colorectal cancer, breast cancer, lymphoma, leukemia, multiple myeloma, liver cancer, gastric cancer, central nervous system (CNS) tumors, pediatric gliomas, ovarian cancer, cervical cancer, colon cancer, pancreatic cancer, prostate cancer and gastric cancer.

[0046] In another aspect, the present invention provides a method for treating a proliferative disease in a mammalian subject, comprising administering to a subject in need thereof a therapeutically effective amount of a modified immune cell, wherein the modified immune cell comprises a loss-of-function mutation in PTCH1 and / or wherein PTCH1 has been silenced or downregulated and / or wherein the PTCH1 gene product has been antagonized. In some embodiments, the loss-of-function mutation in PTCH1 is a mutation that has been found to be present in a human patient with Gorlin syndrome. In some embodiments, the modified immune cell is selected from T cells (including gamma delta (γδ) T cells), CAR-T cells, NK cells, and CAR-NK cells. In some embodiments, the proliferative disease comprises cancer. For example, a cancer selected from the following: melanoma, lung cancer, colorectal cancer, breast cancer, lymphoma, leukemia, multiple myeloma, liver cancer, gastric cancer, central nervous system (CNS) tumors, pediatric gliomas, ovarian cancer, cervical cancer, colon cancer, pancreatic cancer, prostate cancer, and gastric cancer.

[0047] The present invention includes combinations of the described aspects and preferred features except where such combinations are expressly impermissible or explicitly avoided.

[0048] sequence

[0049] Cav1.1 (CACNA1S)

[0050] The amino acid sequence of human Cav1.1 (encoded by CACNA1S) is shown in SEQ ID NO: 1:

[0051]

[0052]

[0053] C av1.2 (CACNA1C)

[0054] The amino acid sequence of human Cav1.2 (encoded by CACNA1C) is shown in SEQ ID NO: 2:

[0055]

[0056] Cav1.3 (CACNA1D)

[0057] The amino acid sequence of human Cav1.3 (encoded by CACNA1D) is shown in SEQ ID NO:3:

[0058]

[0059] Cav1.4 (CACNA1F)

[0060] The amino acid sequence of human Cav1.4 (encoded by CACNA1F) is shown in SEQ ID NO:4:

[0061]

[0062] Cav1.4 (CACNA1F) mutant I745T

[0063] The amino acid sequence of the human CACNA1F I745T mutant is shown in SEQ ID NO: 5. This mutation is also referred to as I756T in the literature (e.g., Williams, 2020). The mutated residue is highlighted in bold and underlined.

[0064] BRIEF DESCRIPTION OF THE DRAWINGS

[0065] Some embodiments and experiments illustrating the principles of the present invention will now be discussed with reference to the accompanying drawings.

[0066] Figure 1 .L-type Cav channel agonists increase Gli1 expression and enhance CD8 + Specific cell killing by CTL. - / - CD8 + T cells and CTL generation. (A) Cells were restimulated for 3 hours on day 9 / 10 using plate-bound anti-CD3ε in the presence of indicated concentrations of FPL 64176 or vector control. RNA was extracted and Gli1 expression was assessed by qRT-PCR. Data are n=3 independent experiments. us=unstimulated cells. (B) LDH cytotoxicity assay using OT-I CTL. On day 7, CTLs were co-cultured with EL-4 cells pulsed with Ova peptide in the presence of 10 μM FPL64176 (squares) or vector control (circles). Data are n=4 independent experiments. (C) Updated experiment of (A). Data are now n=4 independent experiments. Data are normalized relative to Tbp as a reference gene. 0 hours=unstimulated cells. (D) Same data as (B) expressed in a different way. The left figure shows a representative killing assay. The right panel shows quantification of n=4 independent experiments, normalized to killing of cells treated with vehicle at an effector:target ratio of 10:1. Error bars represent SD. p values ​​were calculated using unpaired two-tailed Student's t-test (C) or two-way ANOVA (B / D). * indicates p<0.05, ** indicates p<0.01, and **** indicates p<0.0001.

[0067] Figure 2FPL 64176, but not (R)-baclofen or nefiracetam, enhances Gli1 expression in mouse CD8+ CTLs. - / - naive CD8 + T cells, and CTLs were generated. In the presence of indicated concentrations of (A) FPL64176, (B) (R)-baclofen or (C) nefiracetam (or vehicle control), cells were restimulated using anti-CD3ε mAb. Prior to stimulation, CTLs were pre-incubated with the relevant agent for 40 to 50 minutes (ensuring that the agent (e.g., FPL 64176) had sufficient time to enter the cells). The expression of Gli1 was assessed by qRT-PCR. Data are n=2 independent experiments. Error bars represent SD.

[0068] Figure 3 L-type Cav channel agonists increase GLI1 expression and enhance specific cell killing by human CD8+CTLs. Naive human CD8+T cells were purified from buffy coats isolated from blood of healthy donors and expressed using ImmunoCult TM CD3 / CD28 / CD2 human T cell activator stimulation and restimulation for 3 days again on day 10. (A) Human CTLs were restimulated with plate-bound anti-CD3 for 24 hours on days 15 to 20 in the presence of 10 μM FPL64176 or vector control before RNA extraction for qRT-PCR analysis. n=1 healthy donor. TBP was used as a reference gene. (B) Updated graph of (A) showing n=3 independent experiments / healthy donor. Gli1 expression was normalized to vector. (C) Between days 16 and 24, CD8+ T cells were co-cultured with P815 target cells at the indicated effector to target ratios in the presence of 10 μM FPL64176 (squares) or vector control (circles) and subjected to VITAL cytotoxicity assays. (D) Same data as (C) expressed differently. Representative killing assays are shown on the left. The right panel shows quantification of n=4 experiments performed with 4 different healthy donors, normalized to killing of cells treated with vehicle at a 10:1 effector:target ratio. Error bars represent SD. p values ​​were calculated using unpaired two-tailed Student's t-test (B) or two-way ANOVA (C / D). * indicates p<0.05, ** indicates p<0.01, and **** indicates p<0.0001.

[0069] Figure 4.Gli1 is important for mouse NK cell-specific tumor cell killing. (A) NK cells were isolated from WTC57BL / 6 mice and treated with the Gli1 / Gli2 inhibitor GANT61 (squares) or vehicle control (circles). LDH killing assays (left) and VITAL assays (right) were performed to assess specific cell killing of NK-sensitive RMA / S tumor cells. Left: representative data from n=3 independent experiments. Right: data from 2 separate mice / genotypes. (B) To specifically investigate the contribution of Gli1 to NK cell effector function, LDH killing assays (left) and VITAL assays (right) were performed using NK cells isolated from WT (circles) and Gli1 knockout (KO, squares) mice. Left: representative data from n=2 independent experiments. Right: data from 2 separate mice / genotypes.

[0070] Figure 5 .L-type Cav channel agonists increase GLI1 expression in the human NK cell line NK-92 and promote specific tumor cell killing. (A) NK-92 cells were stimulated with anti-NKp46 mAb for 4 h in the presence of 10 μM FPL 64176, and GLI1 expression was assessed using qRT-PCR. Data are from n=4 independent experiments. (B) NK-92 cells were stimulated with anti-NKp46 mAb for 4 h in the presence of 100 μM Bay K8644, and GLI1 expression was assessed using qRT-PCR. Data are from n=3 independent experiments. (C) LDH assays were performed at the indicated effector to target ratios to assess specific cell killing of K562 target cells in the presence of 10 μM FPL 64176 (right column) or vehicle control (left column). Error bars represent SD. Data are from n=3 independent experiments.

[0071] Figure 6 .Mutation results in a gain-of-function Hh phenotype, and GLI1 expression is increased and specific tumor cell killing of human NK cells is enhanced. NK cells were purified from the buffy coat of blood isolated from patients with Gorlin syndrome and healthy control individuals and cultured for 2 days in complete RPMI+20ng / ml hIL-15. (A) On the second day, GLI1 expression of NK cells was analyzed by qRT-PCR. (B) VITAL assay was performed to assess specific killing of K562 target cells. Data are shown in duplicate, representing NK cells derived from three independent Gorlin syndrome patients (squares) and three healthy control individuals (circles).

[0072] Figure 7NK-92 cells overexpressing the I756T Cav1.4 gain-of-function mutation show enhanced tumor cell killing. NK-92 cells (parent) were engineered to stably express empty vector (EV), Cav1.4 (WT), Cav1.4 with the gain-of-function mutation I756T and the loss-of-function mutation S229P, respectively. Killing of K562 tumor cells was assessed by LDH killing assay after 24 hours. Stable expression of WT, I756T (GOF) or S229P (LOF) Cav1.4 in NK-92 cells did not affect cell survival and proliferation. I756T (GOF) Cav1.4 can also be successfully expressed in human CD8 T cells.

[0073] Figure 8 .Gli1 mediates specific cell killing by mouse cytotoxic CD4+ T cells. Cytotoxic CD4+ T cells were generated from OT-II mice and treated with 5 μM Gli1 / Gli2 inhibitor GANT61 (grey) or vehicle control (black) for 24 hours, followed by LDH assay to assess specific cell killing. Data from n=3 independent experiments.

[0074] Fig. 9 .GzmB content and IFNγ secretion in cytotoxic CD4+ T cells are not affected by Gli inhibition. Cytotoxic CD4+ cells were generated from OT-II mice and treated with 5μM GANT61 or vehicle control for 24 hours on day 7, and then analyzed by flow cytometry for granzyme B (GzmB) and IFNγ levels on day 8. (A) Representative flow cytometric images of unstimulated (upper panel) or restimulated CD4+ T cells (lower panel). (B) Quantification of steady-state GzmB levels and IFNγ levels after restimulation. Data are from n=3 independent experiments.

[0075] Fig.10 .GzmB content and IFNγ secretion in NK cells are not affected by Gli inhibition. NK cells were isolated from C57BL / 6 mice and treated with 10 μM GANT61 or vehicle control (EtOH) overnight (about 18 hours), and then analyzed by flow cytometry for intracellular granzyme B (GzmB) and IFNγ expression. (A) Representative flow cytometry plots. (B) Quantification of flow cytometry plots. Data are from n=2 mice, 1 independent experiment.

[0076] Fig.11 .FPL64176 treatment does not impair naive and cytotoxic CD8 + T cell viability or proliferation does not affect the memory phenotype and is regulated by extracellular Ca 2+Enhanced CTL killing. Naive CD8+ T cells were stimulated with plate-bound anti-CD3 / CD28 antibodies for 24 h in the presence of 10 μM FPL64176 or vehicle control prior to flow cytometry analysis ( Fig.11 A to D). (A) Quantitative analysis of viable cell numbers. (B) Apotracker, an apoptosis marker TM (C) The percentage of cells positive for ANTI Green. (D) Analysis of T cell subsets based on CD44 and CD62L expression: CD44-CD62L+ (naive), CD44+CD62L+ (central memory) and CD44+CD62L- (effector memory). Fig.11 E to G) CTLs were restimulated with plate-bound anti-CD3 antibody on day 10 for 24 h in the presence of 10 μM FPL64176 or vehicle control before flow cytometry analysis. (E) Quantification of viable cell numbers. (F) Apoptosis marker Apotracker TM (G) Percentage of cells positive for the cell viability dye DAPI. (H) Mouse CTLs were co-cultured with ovalbumin-pulsed EL-4 target cells at the indicated effector to target ratios in the presence of 10 μM FPL64176 and / or 1.25 mM BAPTA and their corresponding vehicle controls on days 7 to 8 after stimulation and subjected to a 3-hour LDH cytotoxicity assay. n = 4 independent experiments, normalized to killing of vehicle-treated cells at an effector:target cell ratio of 10:1. Error bars represent SD.

[0077] Fig.12 GLI1 is important for tumor cell killing by human Vγ9Vδ2γδ T cells and treatment with the L-type voltage-gated Ca2+ channel agonist FPL64176 enhances killing capacity. PBMCs were isolated from buffy coats of healthy donors using SepMate PBMC isolation tubes. PBMCs were cultured at 1×10 6Concentrations were plated to induce Vγ9Vδ2 expansion. From day 6 until day 20, cells were split every 2 to 3 days. Killing assays were performed on days 16 to 20. (A) Vγ9Vδ2 T lymphocytes were incubated overnight with the Gli1 / 2 inhibitor GANT61 or EToH (vector control), and then co-cultured with K562 target cells at a specified effector to target ratio for 24 hours, and flow cytometry-based killing assays were performed. n = 1 individual donor. (B) Vγ9Vδ2 cells were pre-incubated with 10 μM FPL64176 or EToH (vector control), and then co-cultured with K562 target cells at a specified effector to target ratio, and flow cytometry cytotoxicity assays were performed in the presence of 10 μM FPL64176 or EToH (vector control). Killing was assessed after 24 hours. Tumor cell killing was normalized to vehicle-treated cells at a 10:1 effector:target ratio. n = 4 individual healthy donors from 2 independent experiments.

[0078] Fig.13 .Treatment of tumor-specific CD8 T cells with the Cav channel agonist FPL64176 and then adoptive transfer into tumor-bearing mice resulted in increased tumor cell death in vivo. In the presence of FPL64176 or a vector control, cytotoxic OTI T cells were restimulated in vitro and then adoptively transferred into MC38-Ova tumor-bearing Rag2 KO mice by tail vein injection. 24 hours after adoptive transfer, tumors were excised and analyzed for cleaved caspase 3 (A) by immunohistochemistry. 3 mice / condition, %CC3 of the entire tumor area of ​​all mice. (B) The experiment was repeated with 3 to 4 mice under each condition. Each data point represents the average CC3 staining of 3 separate tumor sections. Overall CC3 staining (top row) and weak, medium, and strong CC3 staining (bottom row) are shown respectively. FPL treatment may not affect the effector and central memory phenotypes of tumors, spleens, and draining lymph nodes in vivo.

[0079] Fig.14 .L-type voltage-gated Ca 2+ The channel agonist FPL 64176 accelerates Ca2+ expression after TCR cross-linking 2+ Flow initiation and specific enhancement of mouse CD8 + Cav-mediated Ca in cytotoxic T lymphocytes 2+ Flow. Mouse CD8 + CTLs are loaded with the calcium sensor dye eFluor TM514, anti-CD3ε antibody and calcium channel inhibitors / agonists. Other calcium channels expressed in CD8 T cells were inhibited: "Blocking" = BTP 2 inhibits CRAC channels downstream of the TCR, and BCTC inhibits TRPV channels. All inhibitors were non-toxic to T cells at the concentrations used (data not shown). T cell receptor (TCR) cross-linking was induced by adding antibodies to cross-link the TCR 30 seconds after starting sample collection. Arrows indicate the initiation of calcium flux after TCR cross-linking. Lines indicate the calcium sensor dye eFluor TM Baseline fluorescence of 514. Data shown are representative of two independent experiments.

[0080] Fig.15 .GLI inhibitor GANT61 reduces tumor cell killing by human CD8+ cytotoxic T lymphocytes. PBMCs were isolated from buffy coats of healthy donors using SepMate PBMC isolation tubes. CD8+ T cells were isolated using negative selection (Miltenyi Biotec, CD8+ T cell isolation kit) and plated at 25 μl / mL in ImmunoCult® in TexMACS cell culture medium supplemented with 100 IU / mL human IL-2 and 100 U / ml penicillin / streptomycin. TM Human CD3 / CD28 / CD2 T cell activators. Human CTLs were incubated overnight with the Gli1 / 2 inhibitor GANT61 or EToH (vector control) and subsequently co-cultured with anti-CD3ε-pulsed P815 target cells for 3 hours at the indicated effector to target cell ratios and subjected to LDH cytotoxicity assays. (A) Representative graphs, (B) Quantification of N=3 donors, normalized to killing of vector-treated cells at a 10:1 effector:target ratio. Error bars represent SD. n=3 donors from 2 independent experiments. DETAILED DESCRIPTION

[0081] Some aspects and embodiments of the present invention will now be discussed with reference to the accompanying drawings. Other aspects and embodiments will be apparent to those skilled in the art. All documents mentioned herein are incorporated herein by reference.

[0082] Cav channel

[0083] Voltage-gated calcium channels (Ca V s) form a family of 10 members, classified according to the expression of the pore-forming α1 subunit. These 10 members are grouped into three subfamilies: Ca V 1. Ca V 2 and Ca V 3. The Cav1 subfamily is also called the L-type Cav family and includes Ca V 1.1(α1S ), Ca V 1.2(α 1C ), Ca V 1.3(α 1D ) and Ca V 1.4(α 1F ). "L" indicates the "persistent current" associated with this subfamily. The present invention relates to L-type Ca V s.

[0084] Immune cells

[0085] The present invention provides a modified immune cell platform. It is envisioned that the modified immune cell can be any cytotoxic lymphocyte. For example, the modified immune cell can be a CD8+T cell, a CD4+T cell, or a NK cell. The T cell can be a γδT cell. The inventors assume that all cytotoxic lymphocytes rely on Gli1 to exert their cell killing function. Cytotoxic lymphocytes exert their effects on their target cells by releasing granzymes, which are serine proteases that can induce apoptosis of target cells. Granzymes are packaged together with perforins (pore-forming proteins that allow granzymes to enter target cells) in cytotoxic granules. There are five types of granzymes in humans: granzyme A, granzyme B, granzyme H, granzyme K, and granzyme M.

[0086] Renovation

[0087] The engineered immune cell platform can use any suitable genetic engineering technology. The genetic engineering technology can be nuclease-based.

[0088] For example, engineered immune cells can be engineered using CRISPR / Cas9 gene editing. This technology is based on the bacterial antiviral defense system CRISPR-Cas9. The Cas9 nuclease is complexed with a synthetic guide RNA (gRNA) that directs the nuclease to the desired DNA site to be cut by the nuclease.

[0089] Alternatively, prime editing (Anzalone, 2019) can be used to modify the modified immune cells. This genome editing method uses a catalytically impaired Cas9 endonuclease fused to a modified reverse transcriptase, which has a prime editing guide RNA (pegRNA) that specifies the target site and encodes the desired editing at the same time. In this way, new genetic information is written directly into the target DNA site.

[0090] Gain of function

[0091] As used herein, "gain-of-function" (or "gain of function" or "GOF") refers to a modification, such as a mutation, that enhances one or more recognized functions of a gene product. In particular, a gain-of-function mutation (GOF) in an L-type Cav channel can be a mutation that causes the L-type Cav channel to exhibit greater Ca2+ expression in vitro or in vivo compared to an unmutated L-type Cav channel tested under similar conditions. 2+ flow, faster opening, extended opening, accelerated Ca 2+ Initiation of flux, slower inactivation kinetics, or other changes that result in greater calcium channel activity. Some specific examples of L-type Cav channel GOF mutations are described above (see, e.g., Table 1).

[0092] PTCH1

[0093] The protein "Protein patch homolog 1" having a human amino acid sequence disclosed by UniProt Q13635 (UniProt Release 2023_01 as of February 22, 2023) is encoded by the gene PTCH1 (NCBI Gene ID: 5727). Many PTCH1 variants have been reported to be present in human patients with Gorlin syndrome. For example, rs1843916565. All PTCH1 mutations associated with Gorlin syndrome disclosed by UniProt Q13635 (in the section entitled "Disease & Variants") are expressly incorporated herein by reference in their entirety. PTCH1 mutations that cause Gorlin syndrome are considered herein to be PTCH1 loss-of-function mutations.

[0094] Chimeric Antigen Receptor

[0095] Chimeric antigen receptors (CARs) are recombinant receptor molecules that provide both antigen binding and T cell activation functions. CAR structures and modifications are reviewed in, for example, Dotti et al., Immunol Rev (2014) 257 (1), which is incorporated herein by reference in its entirety.

[0096] CAR comprises an antigen binding domain and a signaling domain connected to a transmembrane domain. The optional hinge domain can provide separation between the antigen binding domain and the transmembrane domain and can act as a flexible linker.

[0097] The antigen binding domain of CAR can be based on the antigen binding region of an antibody, which is specific to the antigen targeted by CAR. For example, the antigen binding domain of CAR may include the amino acid sequence of the complementarity-determining region (CDR) of the antibody that specifically binds to the target protein. The antigen binding domain of CAR may include the following or be composed of the following: the light chain and heavy chain variable region amino acid sequences of the antibody that specifically binds to the target protein. The antigen binding domain may be provided as a single chain variable fragment (single chain variable fragment, scFv) of the sequence of the light chain and heavy chain variable region amino acid sequences of the antibody. The antigen binding domain of CAR can be based on other proteins: protein interactions (such as ligand: receptor binding) to target antigens; for example, IL-13Rα2-targeted CAR has been developed using an antigen binding domain based on IL-13 (see, for example, Kahlon et al. 2004 Cancer Res 64 (24): 9160-9166).

[0098] The transmembrane domain is located between the antigen binding domain and the signal transduction domain of CAR. The transmembrane domain provides for anchoring CAR to the cell membrane of the cell expressing CAR, wherein the antigen binding domain is located in the extracellular space, and the signal transduction domain is located on the intracellular side. The transmembrane region of CAR can be derived from the transmembrane region sequence of CD3-ζ, CD4, CD8 or CD28.

[0099] The signaling domain allows activation of T cells. The CAR signaling domain may include an amino acid sequence of the CD3-ζ intracellular domain, providing an immunoreceptor tyrosine-based activation motif (ITAM) for phosphorylation and activation of T cells expressing CAR. Signaling domains containing other ITAM protein sequences have also been used in CARs, such as domains containing ITAM regions of FcγRI (Haynes et al., 2001 J Immunol 166 (1): 182-187). CARs containing signaling domains derived from the CD3-ζ intracellular domain are generally referred to as first generation CARs.

[0100] The signaling domain of CAR may also include a costimulatory sequence derived from the signaling domain of a costimulatory molecule to promote the activation of T cells expressing CAR after binding to the target protein. Suitable costimulatory molecules include CD28, OX40, 4-1BB, ICOS and CD27. CARs with signaling domains comprising additional costimulatory sequences are generally referred to as second generation CARs.

[0101] In some cases, CAR is modified to provide costimulation of different intracellular signaling pathways. For example, the signaling associated with CD28 costimulation preferentially activates the phosphatidylinositol 3-kinase (phosphatidylinositol 3-kinase, PI3K) pathway, while the signaling mediated by 4-1BB is through TNF receptor-associated factor (TNF receptorassociated factor, TRAF) adapter protein. Therefore, the signaling domain of CAR sometimes includes a costimulatory sequence derived from a signaling domain of more than one costimulatory molecule. CARs comprising a signaling domain with multiple costimulatory sequences are generally referred to as third-generation CARs.

[0102] The optional hinge region can provide separation between the antigen binding domain and the transmembrane domain and can act as a flexible linker. The hinge region can be a flexible domain that allows the binding moiety to be oriented in different directions. The hinge region can be derived from the CH of IgG1 or immunoglobulin. 2 CH 3 area.

[0103] Adoptive transfer

[0104] In some embodiments of the present invention, treatment or prevention methods may include adoptive transfer of immune cells, particularly T cells. Adoptive T cell transfer generally refers to the process of obtaining T cells from a subject, generally by extracting a blood sample (T cells are separated from the blood sample). Then, T cells are generally treated or changed in some way, T cells are optionally amplified, and then applied to the same subject or different subjects. Treatment is generally intended to provide a T cell population with certain desired characteristics to a subject, or to increase the frequency of T cells with such characteristics in the subject. For example, the adoptive transfer of CAR-T cells is described in Kalos and June 2013, Immunity 39 (1): 49-60, which is incorporated herein by reference as a whole.

[0105] Some embodiments of the present invention may also include adoptive transfer of NK cells.

[0106] In some embodiments, the subject from which the T cells are isolated is the subject to which the modified T cells were administered (i.e., the adoptive transfer is of autologous T cells). In some embodiments, the subject from which the T cells are isolated is a different subject from the subject to which the modified T cells were administered (i.e., the adoptive transfer is of allogeneic T cells).

[0107] T cell therapy

[0108] T cell therapy can include adoptive T cell therapy, tumor infiltrating lymphocyte (TIL) immunotherapy, autologous cell therapy, engineered autologous cell therapy (eACT) TM ) and allogeneic T-cell transplantation.

[0109] The T cells for immunotherapy can be from any source known in the art. For example, T cells can be differentiated from a hematopoietic stem cell population in vitro, or T cells can be obtained from a subject. T cells can be obtained, for example, from peripheral blood mononuclear cells, bone marrow, lymph node tissue, umbilical cord blood, thymus tissue, tissue from an infected site, ascites, pleural effusion, spleen tissue, and tumors. In addition, T cells can be derived from one or more T cell lines available in the art. T cells can also be obtained using any number of techniques known to those skilled in the art (e.g., FICOLL TM Separation and / or apheresis) is obtained from a unit of blood collected from a subject. Additional methods of isolating T cells for use in T cell therapy are disclosed in US2013 / 0287748, which is incorporated herein by reference in its entirety.

[0110] Gli1 reporter assay

[0111] As described herein, any suitable Gli1 reporter assay can be used. The Gli1 reporter assay can be used to determine the stimulation of L-type Cav channel activity. For example, the Gli1 reporter assay can be any assay that detects binding to the Gli1 consensus sequence. Such an assay can be employed using a fluorescent probe, or can be a colorimetric assay. The Gli1 reporter assay can detect Gli1 mRNA by qRT-PCR. The Gli1 reporter assay can detect Gli1 protein levels and nuclear translocation by immunofluorescence.

[0112] cancer

[0113] "Cancer" may include any one or more of the following: acute lymphocytic leukaemia (ALL), acute myeloid leukaemia (AML), adrenocortical carcinoma, anal cancer, bladder cancer, blood cancer, bone cancer, brain tumor, breast cancer, female reproductive system cancer, male reproductive system cancer, central nervous system lymphoma, cervical cancer, childhood rhabdomyosarcoma, childhood sarcoma, chronic lymphocytic leukaemia (CLL), chronic myeloid leukaemia (CML), colorectal cancer, colon cancer, endometrial cancer, endometrial sarcoma, esophageal cancer, eye cancer, gallbladder cancer, stomach cancer, gastrointestinal cancer, hairy cell leukemia, head and neck cancer, hepatocellular carcinoma, Hodgkin's disease (Hodgkin's disease), hypopharyngeal cancer, Kaposi's sarcoma, kidney cancer, laryngeal cancer, leukemia, leukemia, liver cancer, lung cancer, malignant fibrous histiocytoma, malignant thymoma, melanoma, mesothelioma, multiple myeloma, myeloma, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, nervous system cancer, neuroblastoma, non-Hodgkin lymphoma, oral cancer, oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pituitary tumor, plasma cell tumor, primary CNS lymphoma, prostate cancer, rectal cancer, respiratory system, retinoblastoma, salivary gland cancer, skin cancer, small intestine cancer, soft tissue sarcoma, stomach cancer, gastric cancer, testicular cancer, thyroid cancer, urinary system cancer, uterine sarcoma, vaginal cancer, vascular system, Waldenstrom's macroglobulinemia, and Wilm's tumor.

[0114] The cancer can be of a particular type. Some examples of cancer types include astrocytoma, carcinoma (e.g., adenocarcinoma, hepatocellular carcinoma, medullary carcinoma, papillary carcinoma, squamous cell carcinoma), glioma, lymphoma, medulloblastoma, melanoma, myeloma, meningioma, neuroblastoma, sarcoma (e.g., angiosarcoma, chondrosarcoma, osteosarcoma).

[0115] In a preferred embodiment, the cancer is melanoma, lung cancer, colorectal cancer or breast cancer. Preferably, the cancer may also be lymphoma, leukemia (including acute lymphocytic leukemia and chronic lymphocytic leukemia) or multiple myeloma.

[0116] Treatment of cancer, e.g., using the compositions and / or cells of the invention, can be advantageously combined with other anti-cancer therapies, e.g., with checkpoint inhibitors (e.g., anti-PD-1, anti-PD-L1, anti-CTLA4 antibodies, e.g., nivolumab, atezolizumab, or pembrolizumab).

[0117] Autoimmune diseases

[0118] Autoimmune disease is an inflammatory disease caused by abnormal activation of immune response. Without being bound by theory, it is believed that autoimmune disease can be derived from failure in immunomodulatory process (e.g., failure including thymus selection) or from continuous activation of immune response (e.g., continuous release of damage-associated molecular pattern (DAMP) or pathogen-associated molecular pattern (PAMP)). Autoimmune disease is usually related to the generation of autoreactive autoantibodies and / or autoreactive lymphocytes (e.g., autoreactive T cells and B cells).

[0119] It is well known that autoimmune diseases can affect any area of ​​the body. The term "autoimmune disease" may be any one or more of the following diseases: acquired aplastic anemia, acquired hemophilia, primary agammaglobulinemia, alopecia areata, ankylosing spondylitis (AS), anti-NMDA receptor encephalitis, antiphospholipid syndrome (APS) (including catastrophic antiphospholipid syndrome (CAPS)), autoimmune Addison's disease (AAD), autoimmune autonomic ganglionopathy (AAG), autoimmune gastrointestinal dysmotility (AGID), autoimmune encephalitis (including acute disseminated encephalomyelitis (ADEM)), autoimmune gastritis, autoimmune haemolytic anaemia (AIHA), autoimmune hepatitis (autoimmune hepatitis (AIH), autoimmune myocarditis, autoimmune oophoritis, autoimmune pancreatitis (AIP), autoimmune polyendocrine syndrome (including type I, type II and type III), autoimmune progesterone dermatitis, Balo disease, Behcet's disease, birdshot uveitis, bullous pemphigoid, celiac disease, chronic inflammatory demyelinating polyneuropathy (CIDP), Churg-Strauss syndrome, Cogan's syndrome, cold agglutinin disease, CREST syndrome, Crohn's disease (CD), cutaneous lupus erythematosus, dermatitis herpetiformis, dermatomyositis, Devic's disease, type 1 diabetes, discoid lupus, eosinophilic fasciitis, Evans syndrome syndrome), glomerulonephritis, Goodpasture's syndrome, granulomatosis with polyangiitis,GPA), Graves' disease, Guillain-Barré syndrome (GBS), Hashimoto's thyroiditis, Henoch-Schwann purpura (Henoch- purpura), Hurst's disease, Berger's disease, immune-mediated necrotizing myopathy (IMNM), immune thrombocytopenia (ITP), inflammatory bowel disease (IBD), juvenile idiopathic arthritis, juvenile myositis, Lambert-Eaton myasthenic syndrome (LEMS), linear IgA disease (LAD), lupus nephritis, Ménière's disease, mixed connective tissue disease (MCTD), multiple sclerosis (MS), myasthenia gravis (MG), ocular cicatricial pemphigoid, relapsing rheumatic disease, paraneoplastic cerebellar degeneration, paraneoplastic pemphigus, paroxysmal nocturnal hemoglobinuria (paroxysmal nocturnalhaemoglobinuria (PNH), Parsonage-Turner syndrome, herpes gestationis, pemphigus foliaceus, pemphigus vulgaris, POEMS syndrome, polyarteritis nodosa, polymyalgia rheumatica, polymyositis, primary biliary cirrhosis (PBC), psoriasis, psoriatic arthritis, pure red cellaplasia (PRCA), Raynaud's syndrome, Reiter's syndrome, relapsing polychondritis, rheumatic fever, rheumatoid arthritis (RA), sarcoidosis, Schmidt syndrome, scleroderma, Sjögren's syndrome, small fiber sensory neuropathy, systemic lupus erythematosus (SLE), ulcerative colitis (UC), undifferentiated connective tissue disease (UCTD), and vitiligo.

[0120] Preferably, the autoimmune disease is rheumatoid arthritis (RA), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS) or type 1 diabetes.

[0121] Infectious Diseases

[0122] Infectious diseases are characterized by infection of the patient with an infectious agent and are therefore usually associated with activation of an immune response. Infectious agents may include microorganisms such as viruses, bacteria, protozoa, or fungi. Small animals may be considered infectious agents, commonly referred to as "parasites." Additionally, the term "infectious agent" may also refer to prions.

[0123] Viruses may include hepatitis viruses, adenoviruses, rabies viruses, papillomaviruses, rotaviruses, herpes viruses, cytomegaloviruses, and bacteriophages. In some aspects of the present disclosure, the term "virus" may refer to a human retrovirus, such as HIV. The term "virus" may also refer to a pandemic coronavirus, including the SARS-CoV-II virus.

[0124] Pathogenic bacteria include Staphylococcus, Streptococcus, Neisseria, Clostridium, Bacillus, Listeria, Escherichia, Salmonella, Vibrio, Campylobacter, Bordetella, Haemophilus, Legionella, Helicobacter, Mycobacterium, Treponema, Borrelia, Chlamydia, and Rickettsia species. Pathogenic protozoa include Entamoeba, Trichomonas, Leishmania, Chilomonas, Giardia, Isopora, Sarocystis, Nosema, Balantidium, Histomonas, Trypanosoma, Plasmodium, Babesia, Haemoproteus, and Eimeria species. Pathogenic fungi include Candida, Pneumocystitis, Histoplasma, Blastomyces, Malassezia, and Cryptococcus species. Parasites can include intracellular or extracellular parasites such as Ancylostoma, Ascaris, Enteroblus, Paragonimus, Schitosoma, Taenia, Trichuris, Wuchereria, Balantidium, Entamoeba, Giardia, Leishmania, Plasmodium, Trichomonas, and Trypanosoma species.Infectious diseases caused by prions may include Creutzfeldt-Jakob disease (CJD), variant Creutzfeldt-Jakob disease (CJD), variably protease-sensitive prion disease (VPSPr), Gerstmann-Straussler-Scheinker disease (Gerstmann-Straussler-Scheinker disease). -Scheinker disease (GSS), kuru, and fatal insomnia (FI).

[0125] Preferably, the infectious disease is an infection with HIV, SARS-CoV-II, hepatitis C, hepatitis B, human cytomegalovirus or an opportunistic fungal infection (eg aspergillosis).

[0126] Object

[0127] The subject to be treated according to the present invention can be any animal or human. The subject is preferably a mammal, such as a cat, dog, horse, donkey, sheep, pig, goat, cow, mouse, rat, rabbit or guinea pig, more preferably a human. The subject can be male or female. The subject can be a patient. The subject can have been diagnosed as having a disease or condition (such as cancer) that needs to be treated, can be suspected of having such a disease or condition, or can be at risk of developing such a disease or condition. The subject can be a minor, such as a human child (such as a child with pediatric cancer).

[0128] Features disclosed in the foregoing description, or in the appended claims, or in the drawings, in their specific form, or in terms of a manner for performing a disclosed function, or a method or process for obtaining a disclosed result, may be used, as appropriate, separately or in any combination of such features, to implement the invention in its multiple forms.

[0129] Although the present invention has been described in conjunction with the above exemplary embodiments, many equivalent modifications and variations will be apparent to those skilled in the art when considering the present disclosure. Therefore, the exemplary embodiments of the present invention set forth above are considered to be illustrative rather than restrictive. Various changes may be made to the described embodiments without departing from the spirit and scope of the present invention.

[0130] For the avoidance of any doubt, any theoretical explanations provided herein are provided for the purpose of improving the reader's understanding. The inventors do not wish to be bound by any of these theoretical explanations.

[0131] Any section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

[0132] Throughout this specification (including the appended claims), unless the context requires otherwise, the words "comprise" and "comprising" and variations thereof will be understood to imply the inclusion of stated integers or steps or groups of integers or steps but not the exclusion of any other integers or steps or groups of integers or steps.

[0133] It must be noted that, unless the context clearly indicates otherwise, nouns used in the specification and the appended claims without quantifiers represent one / kind or more / kind. Ranges may be expressed herein as from "about" one particular value and / or to "about" another particular value. When such a range is expressed, another embodiment includes from one particular value and / or to another particular value. Similarly, when a value is expressed as an approximation by using the antecedent "about", it will be understood that the particular value forms another embodiment. The term "about" in relation to a numerical value is optional and means, for example, + / -10%.

[0134] experiment

[0135] The following data are provided to demonstrate the efficacy and therapeutic utility of the present invention. These data are intended to be illustrative and not limiting of the scope of protection. Background Art

[0137] Hedgehog (Hh) signaling is known to control T cell killing by regulating the formation of immune synapses. For example, dela Roche et al. (2013) reported that stimulation of the T cell receptor (TCR) in mouse CD8+ T cells drives Hh activation, which in turn initiates the expression of downstream Hh components, including Gli1. The authors specifically identified a role for Hh signaling in centrosomal polarization and actin reorganization of CTLs, controlling the formation of immune synapses and, therefore, CTL effector function.

[0138] It is also known that Hh signaling in mouse CD8+ T cells is not induced by the administration of extracellular Hh ligands (de laRoche et al. (2013)). Instead, Hh induction occurs by regulating L-type voltage-gated calcium (Cav) channels downstream of the T cell receptor. For example, Hanna et al. (2021) reported that nifedipine-sensitive Cavs can control Gli1 induction in naive CD8+ T cells and CD8+ CTLs after TCR stimulation. It was also reported that Cav1 family channels mediate specific cell killing of mouse CD8+ CTLs in a Gli1-dependent manner, and their function is independent of canonical Hh signaling. The authors also showed that Cav1 family channels are responsible for Gli1 induction in human CTLs. As Fig.15 As shown in , the GLI1 inhibitor GANT61 reduced tumor cell killing by human CD8+ cytotoxic lymphocytes, which is consistent with the known role of Gli1 in tumor cell killing.

[0139] However, calcium signaling is widely accepted to be both highly complex and tightly regulated, and little is known about the role of L-type Cav channel agonists in controlling lymphocyte activation and effector function.

[0140] Experiment 1: L-type Cav agonists specifically enhance Gli1 transcript levels in TCR-stimulated mouse CD8+ CTLs and Enhanced specific tumor cell killing

[0141] To investigate the potential role of L-type Cav channel agonists in modulating CD8+ CTL activation and effector function, CD8+ T cells were isolated from the spleen and inguinal lymph nodes of Rag2- / -OT-I mice, and CTL were generated. For reference, Rag2- / - mice do not develop mature T and B lymphocytes. OT-I mice have a transgene encoding a TCR that recognizes a peptide fragment of chicken ovalbumin (Ova). Rag2- / -OT-I mice facilitate the isolation of naive CD8+ T cell populations. Plates were coated with 2.5 μg / mL anti-CD3ε mAb, and CD8+ CTL were stimulated via TCR for 3 hours in the presence of 5 or 10 μM FPL 64176 (L-type Cav channel agonist) or vehicle control. Note that CD8+ CTL were pre-incubated with FPL 64176 or vehicle control for 40 to 50 minutes prior to stimulation. The expression of Gli1 was assessed using qRT-PCR. As Figure 1 As shown in A and 1C, administration of FPL 64176 resulted in a dose-dependent increase in Gli1 expression in mouse CD8+ CTLs.

[0142] To determine whether the increase in Gli1 expression is associated with an increase in cellular effector function, an LDH cytotoxicity assay was performed. LDH (lactate dehydrogenase) is a stable cytosolic enzyme that is released into the extracellular environment after damage to the plasma membrane. The LDH assay assesses cell viability by measuring LDH enzyme activity in the cell culture supernatant. Briefly, CD8+ CTLs derived from Rag2- / -OT-I mice were incubated with Ova peptide-pulsed EL-4 target cells in the presence of 10 μM FPL64176 or vehicle control. Figure 1 Co-cultures were performed at the effector:target ratios shown in B and 1 D. As shown, within a certain range or effector to target ratios, FPL 64176 administration increased specific cell killing of EL-4 tumor cells by at least 100%, indicating that increased Gli1 expression serves to enhance the effector function of CD8+ CTLs.

[0143] To evaluate whether other clinically approved drugs with potential L-type Cav channel agonist activity in addition to FPL 64176 could enhance Gli1 transcription, CTLs were stimulated in the presence of FPL 64176, (R)-baclofen, and nefiracetam, and Gli1 transcription was assessed using qRT-PCR. 2+ (R)-baclofen acts as a selective GABA B receptor agonists and in some cases have been described as promoting L-type channel currents, and nefiracetam acts as a GABA receptor agonist with some L-type voltage-gated calcium channel agonist activity. A Receptor agonists.

[0144] Briefly, naive CD8+ T cells were isolated from spleen and inguinal lymph nodes of C57BL / 6 wild-type mice, and CTL were generated. Figure 2 A), (R)-baclofen ( Figure 2 B) Nefiracetam Figure 2 C) (or corresponding vehicle control), CTLs were restimulated for 6 hours on plates pre-coated with anti-CD3ε (2.5 μg / ml) antibody. Note that CD8+ CTLs were also pre-incubated with the appropriate agent or vehicle control for 40 to 50 minutes prior to restimulation. RNA was extracted from the cells and the expression of Gli1 was assessed by qRT-PCR. Figure 2As shown in , only FPL64176 successfully enhanced Gli1 expression after TCR activation. In contrast, (R)-baclofen administration had little effect on Gli1 expression, and nefiracetam reduced Gli1 expression by approximately 50%. These data indicate that potent and specific agonists of L-type Cav channels can increase Gli1 expression in mouse CTLs.

[0145] Experiment 2: L-type Cav agonists enhance GLI1 expression in TCR-stimulated naive CD8+ T cells and CTLs and Specific tumor cell killing

[0146] To evaluate the role of L-type Cav channel agonists in controlling human CD8+ T cell activation and effector function, naive primary human CD8+ T cells were purified from buffy coats isolated from healthy donor blood. ImmunoCult TM The cells were stimulated with human CD3 / CD28 / CD2 T cell activator beads for 24 h, and the expression of GLI1 mRNA was assessed by qRT-PCR. Figure 3 As shown in A, FPL 64176 administration resulted in a dose-dependent increase in GLI1 expression. Next, human CD8+ CTLs were restimulated with plate-bound anti-CD3 for 24 hours on days 15 to 20 after initial TCR stimulation in the presence of 10 μM FPL 64176 or vehicle control, and GLI1 mRNA expression was assessed by qRT-PCR. Figure 3 As shown in B, administration of FPL 64176 resulted in increased expression of GLI1. Figure 3 The data in A and 3B together confirm the data generated using mouse CD8+ CTLs as presented in Experiment 1.

[0147] The VITAL assay was then performed to evaluate the effect of L-type Cav agonists on specific tumor cell killing by human CD8+ CTLs. The VITAL assay is a flow cytometry-based assay that is widely used to assess cell killing. It is hypothesized that increased GLI1 expression will result in enhanced specific tumor cell killing. Briefly, CTLs were co-cultured with CFSE-labeled P815 target cells at the indicated effector to target cell ratios in the presence of FPL64176 or vehicle control ( Figure 3C and 3D). Note that CD8+CTLs were also pre-incubated with the appropriate agent or vehicle control for 40 to 50 minutes prior to the VITAL assay. As shown, FPL 64176 administration increased cell killing by approximately 70%, thus supporting the speculation that increased GLI1 expression downstream of L-type Cav channel activation plays a role in enhancing the effector function of CD8+T cells. For clarity, this observation confirms the data generated using mouse CD8+CTLs as provided in Experiment 1.

[0148] Experiment 3 – Gli1 expression is essential for the cytolytic function of mouse NK cells

[0149] It is speculated that the therapeutic effects of L-type Cav channel agonists may be conserved between CD8+ T cells and NK cells. To investigate this hypothesis, NK cells were isolated from the spleen of C57BL / 6 wild-type mice using the MACS negative isolation protocol and expanded in vitro for 7 days in the presence of 500 IU / L IL-2. LDH assays were performed ( Figure 4 , left) and VITAL assay ( Figure 4 , right, RMA tumor target cells are insensitive to NK cell killing and used as reference in the VITAL assay) to assess specific tumor cell killing. Briefly, NK cells were co-cultured with NK-sensitive RMA / S cells in the presence of 5 μM GANT61 or vehicle control. For reference, GANT61 (NSC 136476) inhibits both Gli1 and Gli2 binding to DNA. Figure 4 As shown in A, NK cells administered with GANT61 were found to exhibit approximately 15% reduction in cell killing as measured by the LDH assay compared to NK cells treated with vehicle control. Similarly, specific tumor cell killing ( Figure 4 A, right) was greatly reduced.

[0150] To more specifically elucidate the role of Gli1 on NK cell killing, NK cells were isolated from WT and Gli1- / - (KO) mice. As described above, the cells were co-cultured with RMA / S cells (without GANT61 treatment), and cell killing was assessed using both LDH assay (left panel) and VITAL assay (right panel, with NK-insensitive RMA cells as control). Figure 4 As shown in B, it was found that the reduction in cell killing exhibited by Gli1 KO NK cells was similar in magnitude to that exhibited by GANT61-treated NK cells ( Figure 4 A) Taken together, these data indicate that Gli1 plays an important role in mediating the cytolytic function of NK cells, confirming the data presented in Experiments 1 and 2.

[0151] Experiment 4 - L-type Cav agonists drive Gli1 transcription and promote specific cell killing in human NK cells

[0152] To investigate whether L-type Cav channel agonists can also enhance GLI1 mRNA levels in the human NK cell line NK-92 (a non-Hodgkin lymphoma cell line that expresses Cav1.3 exclusively), NK-92 cells were stimulated for 4 h using anti-NKp46 mAb (5 μg / mL) in the presence of 10 μM FPL 64176 or 100 μM Bay K8644. For reference, Bay K8644 is a structural analog of nifedipine and acts as an L-type Cav channel agonist. The expression of GLI1 was assessed using qRT-PCR. Figure 5 As shown in A, GLI1 expression was increased in NK-92 cells stimulated with anti-NKp46 mAb in the presence of FPL64176 compared to cells stimulated in the presence of vehicle control. No significant increase was observed in unstimulated cells in the presence of FPL64176. Similarly, GLI1 mRNA levels were increased (almost two-fold) in NK-92 cells stimulated with Bay K8644 compared to cells treated with vehicle control (Figure 2A). Figure 5 These observations confirm that the GLI1-inducing effects of Cav agonists are not limited to compound FPL64176, but specifically in NK cells.

[0153] To determine whether the increased expression of GLI1 correlated with increased effector function of NK-92 cells, NK-92 cells were incubated with K562 myeloid leukemia cells in the presence of 10 μM FPL64176 or vehicle control. Figure 5 Effector:target ratios shown in C were co-cultured. Cell killing was assessed using the LDH assay as described previously. Figure 5 As shown in C, FPL64176 administration enhanced target cell killing by NK-92 cells compared to cells administered with a vehicle control.

[0154] In summary, these data confirm the data generated in mouse and human CD8+CTL as provided in Experiments 1 and 2, thereby confirming that the mechanism of action of L-type Cav agonists (including, for example, FPL 64176 and Bay K8644) is conserved in cytotoxic lymphocyte populations. In particular, these data indicate that the effects of L-type Cav channel agonists are at least conserved between mouse and human CD8+CTL and NK cells.

[0155] Experiment 5 – Mutations driving a gain-of-function Hh phenotype enhance specific cell killing by NK cells

[0156] Patients with Gorlin syndrome are known to carry one of a number of possible germline mutations and deletions in the protein repair homolog 1 (PTCH1) gene, PTCH1, which results in loss of PTCH1 function. PTCH1 is a negative regulator of this pathway. Therefore, PTCH1 loss-of-function mutations would enhance canonical Hh signaling and increase GLI1. To assess the effects of PTCH1 mutations, NK cells were isolated from patients with Gorlin syndrome and healthy control individuals and cultured in IL-2 for two days. On day 2, GLI1 mRNA levels were determined by qRT-PCR ( Figure 6 A). As shown, NK cells from Gorlin syndrome patients have higher levels of GLI1 mRNA. Next, NK cells from Gorlin syndrome patients and healthy control individuals were compared with K562 target cells to Figure 6 The effector and target ratio shown in B was co-cultured. As shown in the figure, it was observed that NK cells isolated from patients with Gorlin syndrome acted as more effective killers than NK cells isolated from healthy control individuals. Without wishing to be bound by any particular theory, the inventors believe that methods intended to inhibit, reduce or downregulate PTCH1 function in immune cells - and the associated increase in GLI1 signaling - will reproduce the enhanced cell killing observed in NK cells isolated from patients with Gorlin syndrome. Therefore, immune cells or gene silencing methods modified to reduce PTCH1 function and / or expression (e.g., PTCH1 silencing based on CRISPR or siRNA in immune cells) can provide new immune cell-based therapeutic approaches for treating a variety of cancers.

[0157] To determine whether the increased specific cell killing observed in Gorlin patients could be achieved by engineering cells to express gain-of-function mutations that result in increased Gli1 signaling, NK-92 cells were engineered to stably express the I756T GOF mutation in Cav1.4. Empty vector (EV) and Cav1.4 (WT) were used as controls. The loss-of-function mutation S229P was used as a negative control. K562 tumor cell killing was assessed after 24 hours by LDH killing assay. Figure 7 As shown in , the I756T mutant resulted in increased cell killing. Thus, the functional gain of the non-canonical Hedgehog pathway can be achieved by genetic modification of the Cav channel. These mutations did not affect cell survival and proliferation (data not shown).

[0158] Experiment 6 – Gli1 transcription mediates cytotoxicity in mice CD4+ Specific cell killing by T cells

[0159] Experiments 1, 2, 3, and 4 established that Gli1 transcription is a mediator of specific cell killing in CD8+ CTL and NK cells in humans and mice. To investigate whether Gli1 also plays a role in driving effector functions of CD4+ T cells, cells were isolated from the spleen of OT-II mice and CTL were generated. Cells were treated with GANT61 at a concentration of 5 μM or vehicle control and 24 hours later were incubated with B cells (as target cells) to generate CTL. Figure 8 The effector: target ratios shown in Figure 1 were co-cultured. As shown, CD4+CTLs administered with GANT61 exhibited a 50% reduction in specific cell killing compared to CD4+CTLs administered with a vector control. This observation suggests that the function of Gli1 in promoting cellular effector function is conserved between CD8+ and CD4+CTLs and NK cells, confirming the results of Experiments 1, 2, 3, and 4.

[0160] Experiment 7 - Cytokine production and maintenance of cytolytic effectors in all cytotoxic lymphocytes Affected by Gli1 inhibition

[0161] The data presented in Examples 1 to 6 demonstrate novel TCR-induced regulation of L-type Cav channel-mediated killing through Gli1. To further investigate this, the effects of GANT61 inhibition on granzyme B and IFNγ secretion were investigated. Cytotoxic CD4+ cells were generated from OT-II mice and treated with 5 μM GANT61 or vehicle control for 24 hours on day 7, followed by flow cytometry analysis of granzyme B (GzmB) and IFNγ levels on day 8. NK cells were isolated from C57BL / 6 mice and treated with 10 μM GANT61 or vehicle control (EtOH) overnight (approximately 18 hours), followed by flow cytometry analysis of intracellular granzyme B (GzmB) and IFNγ expression. In cytotoxic CD4+ cells ( Fig. 9 ) and NK cells ( Fig.10 ) In both, GzmB content and IFNγ secretion were not affected by Gli inhibition.

[0162] Fig. 9 and 10 This indicates that the pathway discovered by the inventors is consistent with the reported Ca 2+ The role of the channel differs in its role in cytokine production and maintenance of cytolytic effectors. Interestingly, the inventors have previously shown the same role in cytotoxic CD8+ T cells (De la Roche, 2013), suggesting that this mechanism is common to all cytotoxic lymphocytes.

[0163] Experiment 8 - L-type Cav agonist treatment does not impair CD8 + T cell viability or proliferation, without affecting the memory phenotype, and Extracellular Ca 2+ Enhanced CTL killing

[0164] To ensure that the use of L-type Cav agonists did not adversely affect immune cells, general cellular function was assessed. Naive CD8 + T cells were stimulated with plate-bound anti-CD3 / CD28 antibodies for 24 h and then analyzed by flow cytometry ( Fig.11 A to D). L-type Cav agonists do not affect CD8 + T cell viability or proliferation, such as live cell count analysis (A), apoptosis marker Apotracker TM Green positive cells analysis (B) and cell viability dye DAPI positive cells analysis (C) are shown. In the analysis of T cell subsets based on the expression of CD44 and CD62L - CD62L + (Original), CD44 + CD62L + (central memory) and CD44 + CD62L - After 10 μM FPL64176 or vehicle control, CTL viability and proliferation were maintained after restimulation with plate-bound anti-CD3 antibody for 24 hours on day 10 (E to G). To determine whether Gli1-mediated tumor cell killing requires extracellular Ca 2+ , add the calcium chelator BAPTA to the LDH cytotoxicity assay. If the Gli1 pathway requires extracellular calcium, BAPTA will chelate any extracellular Ca 2+ And thus prevent immune cells from killing. Fig.11 As shown in H, immune cell killing is abolished in the presence of BAPTA. Thus, Gli1-mediated killing is dependent on extracellular Ca 2+ existence.

[0165] Experiment 9-L-type Cav agonists enhance the killing ability of human γδ T cells

[0166] Experiments 1 to 6 show that GLI1 transcription is CD8 + Mediator of specific cell killing in CTL and NK cells and also drives mouse CD4 + To investigate whether GLI1 also plays a role in driving the effector function of γδ T cells, Vy9Vd2 cells were prepared from PBMCs of healthy human donors. Killing assays were performed on days 16 to 20. Fig.12A shows that γδ T cells pretreated with the GLI1 inhibitor GANT61 have reduced killing capacity against K562 target cells. γδ T cells were also pretreated with 10 μM FPL 64176 or ETOH (vehicle control) and then co-cultured with K562 target cells at the indicated effector to target ratios and subjected to flow cytometry cytotoxicity assays. Fig.12 B shows enhanced killing of γδ T cells treated with FPL64176 compared to controls. Thus, Gli1 also controls the killing capacity of γδ T cells, and L-type Cav agonists can enhance killing of these cells.

[0167] Experiment 10 - Cav channel stimulation before adoptive transfer of tumor-specific CD8 T cells into tumor-bearing mice Treatment of tumor-specific CD8 T cells with FPL 64176 resulted in increased tumor cell death in vivo.

[0168] As described above, the present invention can be used for adoptive transfer. To investigate the applicability of Cav channel agonist therapy in an adoptive transfer treatment protocol, cytotoxic OTI T cells were restimulated in vitro in the presence of FPL 64176 or vehicle control and then adoptively transferred into MC38-Ova tumor-bearing Rag2 KO mice by tail vein injection. 24 hours after adoptive transfer, tumors were excised and analyzed for cleaved caspase 3 by immunohistochemistry. Fig.13 A and B show that treatment of tumor-specific T cells with a Cav channel agonist prior to adoptive transfer results in increased tumor cell killing compared to adoptive transfer of T cells not treated with a Cav channel agonist. This data confirms the feasibility of the present invention for adoptive transfer. FPL treatment may not affect effector and central memory phenotypes in tumors, spleens, and draining lymph nodes in vivo (data not shown).

[0169] Experiment 11 - L-type voltage-gated Ca 2 + The effect of the channel agonist FPL 64176 on Ca 2+ The impact of traffic.

[0170] To investigate the mechanism by which L-type Cav agonists exert their effects, we used CD8 + Calcium flux experiments were performed on cytotoxic T lymphocytes. Fig.14 It shows that L-type voltage-gated Ca 2+ Treatment with the channel agonist FPL64176 accelerated Ca2+ expression after TCR cross-linking. 2+ Flow initiated and specifically enhanced mouse CD8 + Cav-mediated Ca2+ in cytotoxic T lymphocytes 2+ flow.

[0171] Summarize

[0172] Cytotoxic lymphocytes, especially CD8+T cells and NK cells, are essential for eliminating infected and malignant cells. With the unprecedented success of immunotherapy using the killing potential of cytotoxic lymphocytes, methods for enhancing their killing potential are being explored. When the results disclosed herein are compared with other methods, the advantages of the present invention can be seen.

[0173] An example described in the art is CD8 + Loss of the transcription factor Bach2 in T cells, as described in Barton (2022). Bach2 is highly expressed in naive T cells and prevents terminal differentiation into effector cells by limiting the expression of TCR-driven genes and by enhancing the generation of memory cells. In addition, Bach2 is essential for the differentiation of stem-like CD8+ T cells, which is essential for in vivo tumor control and response to checkpoint blockade.

[0174] Barton (2022) showed that genetic knockout of Bach2 in CD8+ T cells resulted in a 50% to 75% enhancement in mouse CTL killing in large in vitro populations (Barton 2022 Figure 1 In contrast, the present invention showed a 100% increase in mouse CTL killing (Examples 1 and Figure 1 ). In addition, in Barton (2022), the killing phenotype was partly due to Bach2 - / - Changes in CD8+ T cell differentiation phenotype, differences in the proportion of CD8 T cells in the tested populations, and Bach2 - / - T cell proliferation was enhanced. When CTL were obtained from similar starting populations, CTL killing was enhanced by only 15% to 50% and this was due to enlarged cytolytic granules containing higher levels of lytic proteins.

[0175] The present invention results in greater overall killing without affecting proliferation, differentiation, and overall levels of lysate proteins. This is consistent with Bach2 of Barton (2022). - / - In contrast to T cells, which are expected to undergo terminal differentiation in vivo, the present invention specifically targets the killing mechanism.

[0176] The present invention utilizes a new non-canonical Hedgehog signaling pathway downstream of the TCR, which is independent of NFAT, AP-1 and NFkB signaling and associated calcium flux (Hanna, 2021). Importantly, NFAT has been shown to be a key driver of T cell exhaustion (Martinez, 2015). Therefore, it is expected that the present invention will not induce an exhaustion phenotype.

[0177] The data provided in Experiments 1, 2, 3, and 4 show that L-type Cav agonists play a role in enhancing the expression of Gli1 in mouse and human CD8+CTL and NK cells; and play a role in enhancing specific cell killing of multiple tumor cell types. The data provided in Experiment 7 show that this effect is further extended to CD4+CTL, and Experiment 9 shows that this effect also extends to γδT cells. These are the first experimental data linking L-type Cav channel agonists (such as FPL 64176 and Bay K8644) to Hedgehog activation and Gli1 transcription, and they use L-type Cav channel agonists to enhance the cytotoxic effector function of CD8+CTL, NK cells, and CD4+CTL. Experiment 10 shows that this method can be used for adoptive transfer.

[0178] In summary, the experimental data provided serve to demonstrate the efficacy and therapeutic utility of the present invention, suggesting that L-type Cav agonists and / or immune cells expressing engineered L-type Cav channels may be valuable tools for treating disease.

[0179] References

[0180] Many publications are cited above to more fully describe and disclose the present invention and the prior art in the field to which the present invention belongs. The complete citations of these references are provided below. The entirety of each of these references is incorporated herein by reference.

[0181] Anzalone et al., Search-and-replace genome editing without double-strand breaks or donor DNA. Nature (2019) 576: 149-157

[0182] Badou et al..Emerging roles of L-type voltage-gated and other calcium channels in T lymphocytes. Front Immunol 4, 243 (2013).

[0183] Barton, PR et al. Super-killer CTLs are generated by single genedeletion of Bach2. ​​Eur J Immunol 52, 1776-1788 (2022)

[0184] de la Roche et al.,Hedgehog Signaling Controls T Cell Killing at theImmunological Synapse.Science(2013)

[0185] Hamara-Wahanui et al.,A CACNA 1F mutation identified in an X-linkedretinal disorder shifts the voltage dependence of Cav1.4channelactivation.PNAS(2005)102(21)

[0186] Hanna et al.,Non-canonical Hedgehog signaling through L-type voltagegated Ca 2+ channels controls CD8 + T cell killing.BioR X iv(2021)

[0187] Martinez,G.J.et al.The transcription factor NFAT promotes exhaustionof activated CD8(+)T cells.Immunity 42,265-278(2015).

[0188] Kotturi and Jefferies.Molecular characterization of L-type calciumchannel splice variants expressed in human T lymphocytes.Molecular lmmunology(2005)

[0189] Striessnig,et al.Voltage-Gated Ca 2+-Channel α1-Subunit de novo Missense Mutations: Gain or Loss of Function - Implications for Potential Therapies. Frontiers in Synaptic Neuroscience (2021) 13(634760)

[0190] Williams et al., Functional impact of a congenital stationary night blindness type 2 mutation depends on subiunit composition of Cav1.4 Ca(2+) channels. J Biol. Chem. (2020) 295:17215-17226

[0191] For standard molecular biology techniques, see Sambrook, J., Russel, D.W. Molecular Cloning, A Laboratory Manual. 3ed. 2001, Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press.

Claims

1. An engineered immune cell, wherein the engineered immune cell comprises a gain-of-function mutation in a Cav channel and / or overexpresses an L-type voltage-gated calcium (Cav) channel.

2. The engineered immune cell of claim 1, wherein the engineered immune cell comprises a gain-of-function mutation in CACNA1F.

3. The engineered immune cell of claim 1 or claim 2, wherein the engineered immune cell overexpresses Cav1.4 compared to a wild-type immune cell of the same type.

4. The engineered immune cell of any preceding claim, wherein the CACNA1F mutation comprises I745T.

5. The engineered immune cell of any preceding claim, wherein the engineered immune cell is selected from T cells, CAR-T cells, NK cells and CAR-NK cells.

6. An engineered immune cell for use in medicine, wherein the engineered immune cell comprises a gain-of-function mutation in an L-type Cav channel and / or overexpresses an L-type Cav channel.

7. An engineered immune cell for use in a method of treating cancer in a subject, wherein the engineered immune cell comprises a gain-of-function mutation in an L-type Cav channel and / or overexpresses an L-type Cav channel.

8. The modified immune cell for use according to claim 7, wherein the cancer is selected from melanoma, lung cancer, colorectal cancer, breast cancer, lymphoma, leukemia, multiple myeloma, liver cancer, gastric cancer, central nervous system (CNS) tumors, pediatric gliomas, ovarian cancer, cervical cancer, colon cancer, pancreatic cancer, prostate cancer and gastric cancer.

9. The engineered immune cell for use according to any one of claims 6 to 8, wherein the engineered immune cell comprises a gain-of-function mutation in CACNA1F.

10. The engineered immune cell for use according to any one of claims 6 to 9, wherein the engineered immune cell overexpresses Cav1.4 compared to wild-type immune cells of the same type.

11. The engineered immune cell for use according to any one of claims 6 to 10, wherein the CACNA1F mutation comprises I745T.

12. The modified immune cell for use according to any one of claims 6 to 11, wherein the modified immune cell is selected from T cells, CAR-T cells, NK cells and CAR-NK cells.

13. An L-type Cav channel agonist for use in a method of stimulating the cell-killing activity of immune cells in a subject suffering from a proliferative disease.

14. A pharmaceutical composition comprising immune cells treated with an L-type Cav channel agonist or immune cells mixed with an L-type Cav channel agonist.

15. The pharmaceutical composition of claim 14, for use in a method of stimulating cell killing activity against a target cell population.

16. The L-type Cav channel agonist for use according to claim 13 or the pharmaceutical composition according to claim 14 or 15, wherein the immune cells are selected from T cells, CAR-T cells, NK cells and CAR-NK cells.

17. An in vitro method for enhancing the cell killing activity of an immune cell, comprising contacting an L-type Cav channel agonist with the immune cell, wherein the L-type Cav channel agonist is capable of stimulating L-type Cav channel activity in a Gli1 reporter assay.

18. The method of claim 17, wherein the L-type Cav channel agonist is selected from FPL 64176 and Bay K8644.

19. An in vitro method for engineering immune cells to increase cell killing activity, comprising genetically engineering immune cells to enhance expression of L-type voltage-gated calcium (Cav) channels or stimulate L-type voltage-gated calcium (Cav) channel activity in a Gli1 reporter assay.

20. The method of claim 19, wherein the modification comprises mutating Cav1.4 to introduce a gain-of-function mutation.

21. The method of claim 20, wherein the Cav1.4 mutation comprises I745T.

22. The method of any one of claims 19 to 21, wherein the modification comprises overexpressing Cav1.

4.

23. The method of any one of claims 19 to 22, wherein the modification comprises nuclease- or CRISPR-based editing of the CACNA1F gene.

24. The method of any one of claims 17 to 23, wherein the immune cell is selected from the group consisting of a T cell, a CAR-T cell, a NK cell, and a CAR-NK cell.

25. A method for treating a proliferative disorder in a mammalian subject, comprising administering to a subject in need thereof a therapeutically effective amount of an engineered immune cell, wherein the immune cell comprises a gain-of-function mutation in an L-type Cav channel and / or overexpresses an L-type Cav channel.

26. The method of claim 25, wherein the immune cells are selected from T cells, CAR-T cells, NK cells and CAR-NK cells.

27. A method of treating a proliferative disease in a mammalian subject comprising administering to said subject in need thereof a therapeutically effective amount of an L-type Cav channel agonist.

28. A method for treating a proliferative disease in a mammalian subject, comprising administering to said subject in need thereof a therapeutically effective amount of immune cells treated with an L-type Cav channel agonist.

29. The method of claim 27 or 28, wherein the L-type Cav channel agonist is selected from FPL64176 and BayK8644.

30. An engineered immune cell for use in a method of treating a chronic infection in a subject, wherein the engineered immune cell comprises a gain-of-function mutation in an L-type Cav channel and / or overexpresses an L-type Cav channel.

31. An engineered immune cell for use in a method of treating an autoimmune disease in a subject, wherein the engineered immune cell comprises a gain-of-function mutation in an L-type Cav channel and / or overexpresses an L-type Cav channel.

32. An in vitro method for determining the cytotoxic fitness of an immune cell from a mammalian subject, comprising measuring the level of GLI1 expression in an immune cell from said mammalian subject.

33. The method of claim 32, wherein the immune cell is a modified immune cell.

34. The method of claim 32, wherein the method comprises administering a test agent to the immune cells.

35. The method of claim 34, wherein the test agent is an L-type Cav channel agonist.

36. The method of any one of claims 32 to 35, wherein the immune cell is a CAR T cell, a CARNK cell, a T cell, or a NK cell.

37. An engineered immune cell for use in a method of treating a proliferative disease in a subject, wherein the engineered immune cell comprises a loss-of-function mutation in PTCH1 and / or wherein PTCH1 has been silenced or downregulated and / or wherein the PTCH1 gene product has been antagonized.

38. The engineered immune cell for use according to claim 37, wherein the loss-of-function mutation in PTCH1 is a mutation that has been found to be present in human patients with Gorlin syndrome.

39. The modified immune cell for use according to claim 37 or claim 38, wherein the immune cell is selected from T cells, CAR-T cells, NK cells and CAR-NK cells.

40. A method of treating a proliferative disorder in a mammalian subject, comprising administering to said subject in need thereof a therapeutically effective amount of an engineered immune cell, wherein said immune cell is as defined in any one of claims 37 to 39.

41. The modified immune cell for use according to any one of claims 37 to 39 or The method of claim 40, wherein the proliferative disorder comprises cancer, optionally wherein the cancer is selected from the group consisting of melanoma, lung cancer, colorectal cancer, breast cancer, lymphoma, leukemia, multiple myeloma, liver cancer, gastric cancer, central nervous system (CNS) tumors, pediatric gliomas, ovarian cancer, cervical cancer, colon cancer, pancreatic cancer, prostate cancer, and gastric cancer.

Citation Information

Patent Citations

  • Pharmacologically active pyrrole and pyrazole derivatives

    EP0230110A1

  • Pyrrole derivatives, process for their preparation and pharmaceutical compositions containing them

    EP0300688A1

  • Use of Chimeric Antigen Receptor-Modified T-Cells to Treat Cancer

    US20130287748A1